# The US Oncology Network

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/the-us-oncology-network/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48 |
| Citations | 103,837 |
| City | The Woodlands |
| Country | US |
| Description | The US Oncology Network is a research organisation in The Woodlands, US. OpenAlex records 1,559 works and 103,837 citations for it. 390 researchers list it as their most recent affiliation. |
| Homepage | https://www.usoncology.com/ |
| OpenAlex ID | https://openalex.org/I4210151469 |
| Researchers | 390 |
| ROR ID | https://ror.org/05xc20j70 |
| Type | other |
| Works | 1,559 |

## University papers

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA](https://scholariq.org/papers/sensitive-and-specific-multi-cancer-detection-and-localization-using-methylation/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer](https://scholariq.org/papers/randomized-open-label-phase-iii-trial-of-docetaxel-plus-high-dose-calcitriol/)
- [Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153](https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/)
- [Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)](https://scholariq.org/papers/safety-efficacy-and-patient-reported-health-related-quality-of-life-and-symptom/)

## University top topics

Showing 8 of 25.

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.